Bio Solution Co

Bio Solution Co Operating Cash Flow

The Operating Cash Flow of Bio Solution Co (086820.KQ) as of Oct 22, 2026 is -1.31 B KRW. In the previous year, Operating Cash Flow was -2.29 B KRW — a change of -42.63% (higher).

Operating Cash Flow

-1.31 BKRW

YoY

-42.63%

Last updated:

Operating Cash Flow of Bio Solution Co is 2025 -1.31 B KRW. Operating Cash Flow of Bio Solution Co was 2024 -2.29 B KRW. It decreases by -42.63% higher compared to the previous year.

The Bio Solution Co Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
1.03 B KRW
Jan 1, 2019
-2.61 B KRW
Jan 1, 2020
-1.69 B KRW
Jan 1, 2021
83.29 M KRW
Jan 1, 2022
-3.81 B KRW
Jan 1, 2023
2.16 B KRW
Jan 1, 2024
-2.29 B KRW
Jan 1, 2025
-1.31 B KRW
The Bio Solution Co Operating Cash Flow history
YEAROperating Cash FlowYoY
-1.31 BKRW-42.63%
-2.29 BKRW-205.85%
2.16 BKRW-156.64%
-3.81 BKRW-4,678.83%
83.29 MKRW-104.94%
-1.69 BKRW-35.30%
-2.61 BKRW-353.96%
1.03 BKRW-1,406.75%
-78.53 MKRW-96.21%
-2.07 BKRW+2.74%
-2.02 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Solution Co Stock analysis

What does Bio Solution Co do? Bio Solution Co. Ltd. generates revenue through the manufacturing and distribution of cell therapy products and stem cell applied technologies. The company sells stem water, a cosmetic raw material containing human stem cells with whitening and anti-wrinkling effects, and keratinocyte medication for severe burns. Additionally, it offers chondrocyte therapy for arthritis treatment and develops human tissue models for toxicity and efficacy testing. The primary customers are cosmetic manufacturers and medical institutions seeking advanced therapeutic solutions. The firm's product portfolio includes stem water, keratinocyte medication, and chondrocyte therapy, all leveraging tissue engineering and stem cell technologies. These products target the cosmetic and medical sectors, with stem water appealing to the skincare market and keratinocyte and chondrocyte therapies serving medical applications. The company focuses on developing and commercializing cell-based solutions for both cosmetic and therapeutic uses. Bio Solution Co. Ltd. operates within the cell therapy and stem cell technology sector, providing specialized products that combine tissue engineering with stem cell applications. Its revenue streams are derived from the sale of cosmetic raw materials and medical therapeutics, with an emphasis on innovative, science-backed solutions for skin care and medical treatments. Bio Solution Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Solution Co stock

Operating Cash Flow of Bio Solution Co is -1.31 B KRW in 2025.

Operating Cash Flow of Bio Solution Co changed from -2.29 B KRW to -1.31 B KRW, representing a -42.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Bio Solution Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Bio Solution Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Bio Solution Co

All Key Metrics — Bio Solution Co